WO2004093803A3 - Photochemotherapeutic compounds for use in treatment of pin1-associated states - Google Patents

Photochemotherapeutic compounds for use in treatment of pin1-associated states Download PDF

Info

Publication number
WO2004093803A3
WO2004093803A3 PCT/US2004/011957 US2004011957W WO2004093803A3 WO 2004093803 A3 WO2004093803 A3 WO 2004093803A3 US 2004011957 W US2004011957 W US 2004011957W WO 2004093803 A3 WO2004093803 A3 WO 2004093803A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
photochemotherapeutic
pin1
compounds
associated states
Prior art date
Application number
PCT/US2004/011957
Other languages
French (fr)
Other versions
WO2004093803A2 (en
Inventor
Lere Bao
Amy Kimzey
Original Assignee
Pintex Pharmaceuticals Inc
Lere Bao
Amy Kimzey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pintex Pharmaceuticals Inc, Lere Bao, Amy Kimzey filed Critical Pintex Pharmaceuticals Inc
Publication of WO2004093803A2 publication Critical patent/WO2004093803A2/en
Publication of WO2004093803A3 publication Critical patent/WO2004093803A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention is directed to modulators, e.g., inhibitors, of Pin 1 and Pin 1- related proteins and the use of such modulators for photochemotherapeutic treatment of Pin 1 associated states, e.g., for the treatment of cancer.
PCT/US2004/011957 2003-04-16 2004-04-16 Photochemotherapeutic compounds for use in treatment of pin1-associated states WO2004093803A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46327103P 2003-04-16 2003-04-16
US60/463,271 2003-04-16

Publications (2)

Publication Number Publication Date
WO2004093803A2 WO2004093803A2 (en) 2004-11-04
WO2004093803A3 true WO2004093803A3 (en) 2006-08-03

Family

ID=33310762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/011957 WO2004093803A2 (en) 2003-04-16 2004-04-16 Photochemotherapeutic compounds for use in treatment of pin1-associated states

Country Status (1)

Country Link
WO (1) WO2004093803A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040163A1 (en) * 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
JPWO2006051937A1 (en) * 2004-11-15 2008-05-29 塩野義製薬株式会社 Hetero 5-membered ring derivatives
KR101118768B1 (en) * 2005-03-24 2012-03-20 한국화학연구원 5-3-Aryl-1-pyridyl-1H-pyrazol-4-ylmethylene-thiazolidine-2,4-dione derivatives useful as antitumor agent
KR101118842B1 (en) * 2005-03-24 2012-03-16 한국화학연구원 5-1,3-diaryl-1H-pyrazol-4-ylmethylene-thiazolidine-2,4-dione derivatives useful as antitumor agent
KR101118827B1 (en) * 2005-08-17 2012-03-20 한국화학연구원 5-3-Aryl-1-phenyl-1H-pyrazol-4-ylmethylene-3-alkylcarboxy- rhodanine derivatives useful as antitumor agents
CN1978445B (en) * 2005-12-02 2010-09-01 中国科学院上海药物研究所 Compound serving as human-derived adenoside mononucleoside activated protein kinase activator, and its preparing method and use
JP5191155B2 (en) * 2006-03-27 2013-04-24 大塚製薬株式会社 Medicaments comprising carbostyril compounds
WO2008082537A2 (en) * 2006-12-19 2008-07-10 The General Hospital Corporation Compounds for modulating integrin cd11b/cd18
WO2008094319A2 (en) * 2007-02-01 2008-08-07 The Board Of Regents Of The University Of Texas Sytem Methods and compositions of trail-death receptor agonists/activators
KR20100134063A (en) * 2008-03-25 2010-12-22 더 리전트 오브 더 유니버시티 오브 캘리포니아 Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator
US7947717B2 (en) 2008-07-18 2011-05-24 Burnham Institute For Medical Research Inhibitors of lethal factor protease
US8143269B2 (en) * 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
EP2365969B1 (en) 2008-11-20 2017-03-22 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Novel anti-biofilm agents
US8637558B2 (en) * 2008-12-30 2014-01-28 Industry-Academic Cooperation Foundation, Chosun University Thiazolidinedione derivative and use thereof
US8731655B2 (en) 2009-05-12 2014-05-20 Mallinckrodt Llc Compounds containing acyclic N-N bonds for phototherapy
US9186349B2 (en) * 2009-05-12 2015-11-17 Mallinckrodt Llc Diaza heterocyclic compounds for phototherapy
JP2011057643A (en) * 2009-09-14 2011-03-24 Sumitomo Chemical Co Ltd USE OF COMPOUND FOR INHIBITING 3-TYPE 17beta-HYDROXY STEROID DEHYDROGENASE, AND MEDICINAL COMPOSITION THEREFOR
JP2011057644A (en) * 2009-09-14 2011-03-24 Sumitomo Chemical Co Ltd USE OF COMPOUND FOR INHIBITING 3-TYPE 17beta-HYDROXYSTEROID DEHYDROGENASE, AND MEDICINE THEREFOR
US9023876B2 (en) 2010-07-08 2015-05-05 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
WO2012153775A1 (en) * 2011-05-10 2012-11-15 国立大学法人神戸大学 Thioxothiazolidine derivative having ras function inhibitory effect
EP2838614B1 (en) 2012-04-20 2019-09-11 GB006, Inc. Compositions for regulating integrins
EP3033083A4 (en) * 2013-08-14 2017-06-14 North Carolina Central University A high-throughput assay for identifying small molecules that modulate amp-activated protein kinase (ampk)
WO2016077793A1 (en) * 2014-11-14 2016-05-19 Children's Hospital Medical Center Sos1 inhibitors for cancer treatment
EP3221299A1 (en) 2014-11-21 2017-09-27 BSIM2 Biomolecular Simulations Lda. 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof
CN107382996B (en) * 2017-06-30 2020-11-06 中国农业大学 Specific inhibition plant plasma membrane H+-ATPase compound and preparation method and application thereof
CN107698577B (en) * 2017-10-23 2020-08-11 广东工业大学 Benzimidazole derivative, preparation method thereof and application thereof in tumor resistance
IT201800003680A1 (en) * 2018-03-16 2019-09-16 Univ Degli Studi Di Siena ANTIVIRAL COMPOUNDS AND USES OF THEM
KR102308134B1 (en) * 2018-04-26 2021-10-01 재단법인 의약바이오컨버젼스연구단 Novel compounds as mTOR inhibitor and uses thereof
KR102297501B1 (en) * 2018-06-08 2021-09-02 재단법인 의약바이오컨버젼스연구단 Composition for preventing or treating cancer comprising novel mTOR inhibitor
CN108658891B (en) * 2018-07-03 2020-09-29 河南农业大学 2-Thiothiazolidin-4-one, derivatives and process for their preparation
US10689374B1 (en) * 2019-07-12 2020-06-23 United Arab Emirates University Pyrimidine-thiazolidinone derivatives
US11292776B2 (en) * 2019-12-12 2022-04-05 University Of Sharjah Small molecule inhibitors of fungal hyphae and biofilm formation
CN111333614B (en) * 2020-04-14 2021-01-15 遵义医科大学珠海校区 Quinolinone compounds and use thereof
KR102539761B1 (en) * 2020-12-23 2023-06-02 계명대학교 산학협력단 2-thioxothiazolidin-4-one derivatives and uses thereof
CN113307788B (en) * 2021-05-28 2022-07-29 赣南师范大学 Near-infrared xanthene fluorescent probe and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002377A1 (en) * 1999-07-01 2001-01-11 Geron Corporation Telomerase inhibitors and methods of their use
WO2001057006A1 (en) * 2000-02-03 2001-08-09 F. Hoffmann-La Roche Ag Thiazolidine carboxylic acid derivatives and their use in the treatment of cancer
US6518268B1 (en) * 1999-07-01 2003-02-11 Geron Corporation Telomerase inhibitors and methods of their use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002377A1 (en) * 1999-07-01 2001-01-11 Geron Corporation Telomerase inhibitors and methods of their use
US6518268B1 (en) * 1999-07-01 2003-02-11 Geron Corporation Telomerase inhibitors and methods of their use
WO2001057006A1 (en) * 2000-02-03 2001-08-09 F. Hoffmann-La Roche Ag Thiazolidine carboxylic acid derivatives and their use in the treatment of cancer
US6506755B2 (en) * 2000-02-03 2003-01-14 Hoffmann-La Roche Inc. Thiazolidinecarboxyl acids

Also Published As

Publication number Publication date
WO2004093803A2 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
WO2004093803A3 (en) Photochemotherapeutic compounds for use in treatment of pin1-associated states
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
WO2005048948A3 (en) Urea derivatives as kinase modulators
WO2003101401A3 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
WO2003032916A3 (en) Organosulfur inhibitors of tyrosine phosphatases
WO2003080582A3 (en) Fredericamycin derivatives
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2004006858A3 (en) Compounds, compositions, and methods employing same
EP1638950A4 (en) Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2006015263A3 (en) Lonidamine analogs
AU2003213144A1 (en) Alkylating agent combinations in the treatment of cancer
EP1859793A4 (en) Novel combinational use of sulfonamide compound
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
WO2004041269A3 (en) New use for pharmaceutical composition
WO2006099610A3 (en) Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
WO2004112829A3 (en) Compositions and methods for the diagnosis and treatment of tumors of glial origin
PL1654253T3 (en) Substituted 3-pyrrolidin-indole derivatives
WO2006019982A3 (en) Pin1-modulating compounds and methods of use thereof
WO2003015608A3 (en) Combination therapy for the treatment of cancer
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
WO2002096348A3 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase